pipeline & platform

Pharvaris has a platform of novel, potent and selective B2-receptor antagonist small molecules for the treatment of B2-receptor-mediated diseases. PHA121, the company’s most advanced program, is designed to treat all sub-types of hereditary angioedema (HAE).

B2-receptor-mediated diseases

We have identified and are developing an orally bioavailable small-molecule bradykinin B2 receptor antagonist with high therapeutic potential.

Bradykinin has a high affinity and high agonist potency at the bradykinin B2 receptor, but a near 1000-fold lower affinity and potency at the bradykinin B1 receptor, making it a selective B2 agonist. Bradykinin activates the bradykinin B2 receptor, resulting in increased permeability of blood vessels, release of fluid into surrounding tissue and edema (swelling). Multiple pathological conditions can result in the overabundance of bradykinin. Blocking bradykinin signaling through its B2-receptor will inhibit all bradykinin biological activities in all circumstances.

PHA121 is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor and is currently in Phase 1 clinical development for the treatment of HAE. PHA121 utilizes the same mechanism as icatibant, the leading therapy for on-demand treatment of HAE. Emerging clinical data from the ongoing Phase 1 study in healthy volunteers confirm PHA121’s oral bioavailability and rapid exposure and demonstrate that PHA121 has been observed to be safe and well-tolerated at the doses studied to date.

PHVS416 is a soft capsule formulation containing PHA121. Pharvaris is developing this formulation to provide rapid exposure of attack-mediating medicine in a convenient, small oral dosage form.

PHVS719 is a tablet formulation containing PHA121. Pharvaris is developing this formulation to provide prolonged preventive treatment in a convenient, small oral dosage form.